caa a22 4500 397592949 CHVBK 20180308164944.0 cr unu---uuuuu 161202e199604 xx s 000 0 eng 10.1093/jac/37.4.775 doi (NATIONALLICENCE)oxford-10.1093/jac/37.4.775 Clinical pharmacokinetics of meropenem after the first and tenth intramuscular administration [Elektronische Daten] [A. Novelli, T. Mazzei, E. Meli, S. Conti, S. Fallani, P. Periti] We investigated the pharmacokinetics of meropenem after the first and tenth im administration in patients with respiratory tract infections. Ten patients (mean age 63.8±5.2 years) received meropenem 500 mg tds for at least ten doses, and plasma and urine antibiotic concentrations were determined by microbiological assay. After the first injection a mean peak plasma concentration of 7.93±1.29 mg/L was observed at 1 h. Trough levels at 8 h (0.29±0.16 mg/L) were detectable in five of ten treated patients. The mean terminal half-life was 1.08±0.2 h with an area under the curve (AUC) value of 23.8±4.59 mg/L.h, and a cumulative urinary recovery at 8 h of 48.43±3.12%. There was no evidence of change in the pharmacokinetics of ineropenem after repeated im administration, though the mean peak plasma concentration and AUC value were slightly increased. The accumulation ratio (assessed using AUC values) was 1.18±0.19 after multiple doses and was considered to be of little kinetic and clinical importance. Moreover, many of the trough concentrations of meropenem were below the limit of detection of the assay. After im administration meropenem concentrations exceeded 0.5 mg/L for longer than previously described following iv infusion. No adverse events were reported. © 1996 The British Society for Antimicrobial Chemotherapy Original articles nationallicence Novelli A. Department of Pharmacology, University of Florence V. le G.B. Morgagni 65, 50134; Italy aut Mazzei T. Department of Pharmacology, University of Florence V. le G.B. Morgagni 65, 50134; Italy aut Meli E. Pneumology Unit Public Health Clinic 10/D, Florence, Italy aut Conti S. Department of Pharmacology, University of Florence V. le G.B. Morgagni 65, 50134; Italy aut Fallani S. Department of Pharmacology, University of Florence V. le G.B. Morgagni 65, 50134; Italy aut Periti P. Department of Pharmacology, University of Florence V. le G.B. Morgagni 65, 50134; Italy aut Journal of Antimicrobial Chemotherapy Oxford University Press 37/4(1996-04), 775-781 0305-7453 37:4<775 1996 37 jac https://doi.org/10.1093/jac/37.4.775 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1093/jac/37.4.775 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Novelli A. Department of Pharmacology, University of Florence V. le G.B. Morgagni 65, 50134; Italy aut NATIONALLICENCE 700 1- Mazzei T. Department of Pharmacology, University of Florence V. le G.B. Morgagni 65, 50134; Italy aut NATIONALLICENCE 700 1- Meli E. Pneumology Unit Public Health Clinic 10/D, Florence, Italy aut NATIONALLICENCE 700 1- Conti S. Department of Pharmacology, University of Florence V. le G.B. Morgagni 65, 50134; Italy aut NATIONALLICENCE 700 1- Fallani S. Department of Pharmacology, University of Florence V. le G.B. Morgagni 65, 50134; Italy aut NATIONALLICENCE 700 1- Periti P. Department of Pharmacology, University of Florence V. le G.B. Morgagni 65, 50134; Italy aut NATIONALLICENCE 773 0- Journal of Antimicrobial Chemotherapy Oxford University Press 37/4(1996-04), 775-781 0305-7453 37:4<775 1996 37 jac Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-oxford